SEC Form 4 · accession 0000899243-17-003419
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sven Ante Lundberg
Officer — Chief Scientific Officer
Period of report
Oct 24, 2016
Accepted (ET)
Feb 10, 2017 · 2:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Oct 24, 2016 | C | 55,217 | $0.00 | A | 505,217 | D | |
| Common Shares | Oct 24, 2016 | P | 400 | $14.00 | A | 505,617 | I | By wife |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred SharesF1 | $0.00 | Oct 24, 2016 | C | 55,217 | D | — | — | Common Shares | 55,217 | 0 | D |
Explanation of responses
- F1These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.